Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Published byWinifred McKenzie Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Carotid artery inflammation detected using 18F-FDG-PET"— Presentation transcript:

1 Figure 1 Carotid artery inflammation detected using 18F-FDG-PET
Figure 1 | Carotid artery inflammation detected using 18F-FDG-PET. Axial CT (left), 18F-FDG-PET/CT (centre) and 18F-FDG-PET (right) scans showing tracer uptake in a culprit atheroma in the right common carotid artery (white arrow). FDG, fluorodeoxyglucose. Scale bar: standardized uptake values (SUV). Evans, N. R. et al. (2017) PET imaging of the neurovascular interface in cerebrovascular disease Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Figure 1 Carotid artery inflammation detected using 18F-FDG-PET"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Figure 4 PET imaging in experimental pancreatic cancer

Figure 4 PET imaging in experimental pancreatic cancer
Fig. 2. Arterial fluorodeoxyglucose (FDG) uptake related to atherosclerosis. On positron emission tomography (PET) coronal (A), PET/CT fusion coronal (B),

Fig. 2. Arterial fluorodeoxyglucose (FDG) uptake related to atherosclerosis. On positron emission tomography (PET) coronal (A), PET/CT fusion coronal (B),
Fig F-fluoride positron emission tomography (PET) in atherosclerosis

Fig F-fluoride positron emission tomography (PET) in atherosclerosis
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Circ Cardiovasc Imaging

Circ Cardiovasc Imaging
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 4 Time course of the development of physiological changes

Figure 4 Time course of the development of physiological changes
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Jenny Dave, MS, Mark A. Ahlman, MD, Benjamin N. Lockshin, MD, David A

Jenny Dave, MS, Mark A. Ahlman, MD, Benjamin N. Lockshin, MD, David A
Figure 2 Overview of risk factors for Parkinson disease dementia

Figure 2 Overview of risk factors for Parkinson disease dementia
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Proportion of patients for whom NEDA

Figure 3 Proportion of patients for whom NEDA
Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 4 Neuromyelitis optica spectrum disorder brain lesions
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Similar presentations

Ads by Google